Search Results - Janis M. Taube
- Showing 1 - 20 results of 110
- Go to Next Page
-
1
-
2
-
3
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy by Tricia R. Cottrell, Janis M. Taube
Published 2018Revisão -
4
Neoadjuvant checkpoint blockade for cancer immunotherapy by Suzanne L. Topalian, Janis M. Taube, Drew M. Pardoll
Published 2020Revisão -
5
Merkel Cell Carcinoma: Update and Review by Timothy S. Wang, Patrick J. Byrne, Lisa K. Jacobs, Janis M. Taube
Published 2011Revisão -
6
-
7
-
8
Inverse Relationship between Human Papillomavirus-16 Infection and Disruptive<i>p53</i>Gene Mutations in Squamous Cell Carcinoma of the Head and Neck by William H. Westra, Janis M. Taube, Maria Luana Poeta, Shanaz Begum, David Sidransky, Wayne M. Koch
Published 2008Artigo -
9
-
10
-
11
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade by Evan J. Lipson, Mohammed Lilo, Aleksandra Ogurtsova, Jessica Esandrio, Haiying Xu, Patricia Brothers, Megan D. Schollenberger, William H. Sharfman, Janis M. Taube
Published 2017Artigo -
12
Detection of Transcriptionally Active High-risk HPV in Patients With Head and Neck Squamous Cell Carcinoma as Visualized by a Novel E6/E7 mRNA In Situ Hybridization Method by Justin A. Bishop, Xiao-Jun Ma, Hongwei Wang, Yuling Luo, Peter B. Illei, Shanaz Begum, Janis M. Taube, Wayne M. Koch, William H. Westra
Published 2012Artigo -
13
Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas by Ashley Cimino‐Mathews, Andrea P. Subhawong, Hillary Elwood, Hind Nassar Warzecha, Rajni Sharma, Ben Ho Park, Janis M. Taube, Peter B. Illei, Pedram Argani
Published 2012Artigo -
14
-
15
Expression profile and in vitro blockade of programmed death‐1 in human papillomavirus–negative head and neck squamous cell carcinoma by Ian‐James Malm, Tullia C. Bruno, Juan Fu, Qi Zeng, Janis M. Taube, William H. Westra, Drew M. Pardoll, Charles G. Drake, Young J. Kim
Published 2014Artigo -
16
-
17
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy by Janis M. Taube, Alison Klein, Julie R. Brahmer, Haiying Xu, Xiaoyu Pan, Jung Ho Kim, Lieping Chen, Drew M. Pardoll, Suzanne L. Topalian, Robert A. Anders
Published 2014Artigo -
18
PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast by Elizabeth D. Thompson, Janis M. Taube, Rebecca J Asch-Kendrick, Aleksandra Ogurtsova, Haiying Xu, Rajni Sharma, Alan K. Meeker, Pedram Argani, Leisha A. Emens, Ashley Cimino‐Mathews
Published 2017Artigo -
19
-
20
Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma by Sheila F. Faraj, Enrico Munari, Güneş Güner, Janis M. Taube, Robert A. Anders, Jessica Hicks, Alan K. Meeker, Mark Schoenberg, Trinity J. Bivalacqua, Charles G. Drake, George J. Netto
Published 2015Artigo
Search Tools:
Related Subjects
Medicine
Internal medicine
Cancer
Cancer research
Immunotherapy
Immunology
Oncology
Biology
Immune system
Pathology
Melanoma
Biochemistry
Immune checkpoint
Immunohistochemistry
Tumor microenvironment
PD-L1
Nivolumab
Breast cancer
CD8
Gene
Receptor
Tumor-infiltrating lymphocytes
Blockade
Lung cancer
Genetics
Chemotherapy
Neoadjuvant therapy
Carcinoma
T cell
Surgery